OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

2,283 VRTX shares were withheld to cover taxes or exercise cost (Officer) | OQRO

Home
Insider trades
Vertex Pharmaceuticals
2,283 VRTX shares were withheld to cover taxes or exercise cost (Offic

Insider trades

Insider trade

2,283 VRTX shares were withheld to cover taxes or exercise cost (Officer)

Traded Feb 13, 2026 · Filed Feb 18, 2026

VRTVertex PharmaceuticalsVRTX

2,283
Shares · @ $487.76

Why it stands out

Routine share withholding; mechanical by default.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 13, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 18, 2026

OfficerTax withholding

Context

Classification

tax withholding

Code F — shares delivered to pay exercise price or tax liability

Planned / mechanical clue

Tax mechanics (code F)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000875320-26-000068

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Feb 18, 2026, 9:32 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

VERTEX PHARMACEUTICALS INC / MA

Issuer CIK

875320

Ticker

VRTX

Reporting person

Mark E. Bunnage

Relationship

Officer

Officer title

EVP, Chief Scientific Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Feb 13, 2026

Transaction code

Shares / units

2,283

Price per share

$487.76

Acquired / disposed

Disposed (D)

Shares owned after

10,631

Ownership form

Direct

Amendment

Around the same time

Carmen Bozic (EVP and CMO) sold ~$1.12M of Vertex Pharmaceuticals

Scheduled in advanceFiled 7mo ago

Duncan Mckechnie (EVP, Chief Commercial Officer) sold ~$1.31M of Vertex Pharmaceuticals

Scheduled in advanceFiled 7mo ago

Duncan Mckechnie (EVP, Chief Commercial Officer) sold ~$1.16M of Vertex Pharmaceuticals

Scheduled in advanceFiled 7mo ago